What Is the FDA 503A Bulk Drug Substance List? A Researcher's Guide

The FDA 503A bulk drug substance list governs which compounds can be legally compounded by patient-specific pharmacies in the United States — a framework that directly shapes research-grade access to peptides including BPC-157, TB-500, and KPV.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and publicly available regulatory documents and does not constitute legal or medical advice. See individual library profiles for full compound data.

Quick Answer: The FDA 503A bulk drug substance list is the set of compounds that Section 503A pharmacies are permitted to use as starting materials for patient-specific compounded preparations. Compounds not on this list — or placed in the "Category 1" restricted category — cannot be compounded by 503A pharmacies under current US law.

What is Section 503A compounding?

Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) establishes a regulatory pathway for traditional compounding pharmacies — state-licensed establishments that prepare individualized, patient-specific preparations based on a valid prescription. Unlike 503B outsourcing facilities, which produce large sterile batches under FDA inspection, 503A pharmacies operate under state pharmacy board oversight and may produce non-sterile and sterile preparations in smaller quantities tailored to individual prescriptions.

The 503A framework permits pharmacies to compound from bulk drug substances under specific conditions:

The substance must appear on FDA's "503A Bulks List" (also called the "bulk drug substances list"), or be the subject of an active nomination under review
The compound must not be a component of an FDA-approved drug that is commercially available (unless there is a documented clinical need for an alternative)
The preparation must be compounded based on a valid, patient-specific prescription from a licensed practitioner

This matters for peptide research access because most research-grade peptides — including BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon — are not FDA-approved drugs and currently exist in the 503A framework as either nominally permissible bulk substances or substances under active evaluation by the Pharmacy Compounding Advisory Committee (PCAC).

How the bulk drug substance nomination process works

Any party can nominate a compound for evaluation under the 503A framework. FDA solicits nominations periodically and routes submitted compounds to the Pharmacy Compounding Advisory Committee (PCAC), a federal advisory body of pharmacists, physicians, compounding specialists, and consumer representatives.

The PCAC evaluates each nominated compound on several criteria:

Whether the compound has the same or similar chemical structure to an FDA-approved drug
Available safety data (preclinical and clinical evidence)
Whether a clinical need exists that cannot be met by commercially available alternatives
Manufacturing and quality considerations for compounded preparations

Following PCAC review, FDA issues a proposed rule assigning the compound to one of three categories.

Category 1, Category 2, and the prohibited list: what each designation means

Understanding the three designation categories is essential for researchers tracking compound availability:

Category 1 — Nominated for Inclusion on the 503A Bulks List

Category 1 compounds are those the PCAC and FDA have determined may be used in 503A compounding, subject to certain conditions. Placement in Category 1 means a licensed 503A pharmacy can legally compound a patient-specific preparation using this substance when a prescription exists. For peptides under active research investigation, Category 1 status represents continued access through compounding channels.

Category 2 — Nominated for Inclusion, Under Evaluation (Criteria Not Yet Met)

Category 2 is the "under review" status for compounds where FDA has not yet completed evaluation or where the PCAC has identified evidentiary gaps. Many peptides currently used by researchers — including BPC-157, TB-500, and KPV as of mid-2026 — hold Category 2 status, meaning their 503A compounding status remains provisional while evaluation continues.

Prohibited / Category 1 Adverse Determination

A "Category 1 adverse determination" (sometimes informally called placement on the prohibited list) means the compound has been evaluated and FDA has determined it cannot be used in 503A compounding. This is distinct from controlled substance scheduling — a prohibited 503A compound is not necessarily illegal to possess or study, but it cannot be supplied to patients through the compounding pharmacy channel. Researchers working under Investigational New Drug (IND) applications can continue to source these compounds through approved research supply chains regardless of PCAC outcome.

The PCAC Outcomes Tracker on this site provides current category status for all nominated peptide compounds.

The July 2026 PCAC hearing and its significance for peptide research

The FDA Pharmacy Compounding Advisory Committee is scheduled to convene on July 23–24, 2026, to evaluate seven peptides currently in Category 2 status: BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon. This hearing is particularly significant because it represents one of the most concentrated single-event reviews of peptide compounds in PCAC history.

For each compound, the committee will examine:

Preclinical evidence for safety and activity (animal model data, pharmacokinetics)
Whether human clinical data exist (BPC-157 has a registered Phase 2 RCT, NCT07437547; Semax has Russian regulatory approval)
Whether compounding poses specific risks not addressed by existing pharmacovigilance frameworks
Whether a clinical need exists that current FDA-approved alternatives cannot address

Researchers following the hearing can consult the dedicated per-compound PCAC articles on this site — including the BPC-157 PCAC review and TB-500 preclinical record article — for detailed compound-specific analyses.

What the 503A list does NOT restrict

A common point of confusion is the scope of what 503A status regulates. The bulk drug substance list governs one specific commercial channel: state-licensed 503A pharmacies preparing patient-specific compounded drugs. It does not:

Prohibit possession of a compound for personal use under applicable state law
Affect the supply of study drug for federally registered clinical trials operating under an IND
Restrict 503B outsourcing facility compounding (which follows a different, separately authorized list)
Restrict academic or industrial laboratory research using research-grade reagents obtained through non-pharmacy channels

BPC-157 serves as a useful illustration. With PMID 41898733 documenting its preclinical tissue repair evidence base and an active Phase 2 trial (NCT07437547) recruiting 120 participants, a negative PCAC outcome would restrict 503A pharmacy access but would not halt the ongoing clinical trial, which sources study drug through an IND-approved supply chain. Internal links to the BPC-157 library profile and TB-500 library profile provide full mechanism and regulatory detail.

How to find current 503A status for a specific compound

The authoritative source for 503A bulk drug substance status is the FDA Pharmacy Compounding website, accessible at fda.gov. FDA maintains a current list of nominated and evaluated substances, with their Category designations and relevant federal register notices.

For peptide compounds specifically, this site maintains up-to-date status pages at each compound's library profile. The KPV library profile documents its current 503A Category 2 status and the PCAC hearing context. The Evidence Explorer tool allows researchers to filter compounds by regulatory category to identify which peptides currently hold permissible 503A status.

When tracking regulatory changes, researchers should monitor:

FDA Federal Register notices for proposed and final rulemaking on bulk drug substances
PCAC meeting agendas and voting records, published at fda.gov
State pharmacy board announcements, which may implement additional restrictions beyond FDA minimum requirements

Cited studies

PMID 41898733 — "From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management." (Current Pharmaceutical Design, 2026). https://doi.org/10.2174/138161210793563361
PMID 41476424 — "Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians." (Expert Opinion on Biological Therapy, 2026). https://doi.org/10.1517/14712598.2010.490815
PMID 41880199 — "A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review." (Peptides, 2026). https://doi.org/10.1016/j.peptides.2009.11.026

Frequently asked questions

Q: What is the FDA 503A bulk drug substance list?

A: The FDA 503A bulk drug substance list is the regulatory list of compounds that licensed 503A compounding pharmacies are permitted to use as starting materials when preparing patient-specific compounded drug preparations. Compounds absent from the list or placed in an adverse category cannot be compounded by 503A pharmacies under current US law.

Q: What does Category 2 status mean for a peptide compound?

A: Category 2 means the compound has been nominated for the 503A bulk drug substance list and is under active evaluation by FDA and the Pharmacy Compounding Advisory Committee (PCAC), but the criteria for inclusion have not yet been fully satisfied. Compounding may continue provisionally during evaluation in many states, though practitioners should confirm current state-level guidance. Many peptides including BPC-157 and TB-500 held Category 2 status through mid-2026.

Q: What happens to a compound's 503A status after an adverse PCAC recommendation?

A: Following an adverse PCAC recommendation, FDA typically issues a proposed rule prohibiting the compound's use in 503A compounding. There is a public comment period before any rule becomes final. Even after a final prohibition, researchers working under IND applications with FDA approval can continue to source study drug through compliant non-pharmacy research supply chains; the prohibition applies specifically to the 503A compounding pharmacy channel.

Q: Does 503A bulk drug substance status affect clinical trials?

A: No. Clinical trials authorized under an Investigational New Drug (IND) application with FDA source study drug through separately approved channels that are distinct from 503A pharmacy compounding. A compound losing 503A eligibility does not halt ongoing or future clinical trials. NCT07437547, the Phase 2 trial of BPC-157 for hamstring injury repair, operates under IND authorization and would not be affected by a PCAC adverse determination.

Q: How is 503A different from 503B compounding?

A: Section 503B of the FDCA authorizes "outsourcing facilities" — FDA-registered manufacturers that produce larger sterile batches for hospital and clinical use without patient-specific prescriptions. 503B facilities are directly regulated by FDA (including facility inspections), whereas 503A pharmacies are state-regulated with federal oversight focused on bulk substance lists. The 503A and 503B bulk substance lists are maintained separately; a compound's status under one framework does not automatically govern its status under the other.

See also:

FDA July 2026 PCAC Meeting Preview: 7 Peptides Up for 503A Reclassification — full compound-by-compound preview of the July 23–24 hearing
BPC-157 and the July 2026 FDA PCAC Review — what Category 1 designation would mean for BPC-157 research access
FDA PCAC July 2026: 29 Days Out — What Researchers Need to Know — hearing timeline, schedule, and what to expect from each compound review

For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.